ArticleWiener klinische Wochenschrift2025
The impact of anti-HBc positivity on clinical outcomes and treatment response in immune thrombocytopenia.
Article in Wiener klinische Wochenschrift, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeImmune thrombocytopenia (ITP) is an autoimmune disorder characterized by low platelet counts due to the destruction of platelets by autoantibodies. The presence of hepatitis B core antibodies (anti-HBc) is a marker of previous or occult hepatitis B virus (HBV) infection, which may influence the clinical course and treatment outcomes in ITP patients.
methodsThis retrospective study investigated the impact of anti-HBc positivity on the clinical outcomes and response to treatment in ITP patients. A total of 116 patients with ITP were divided into 2 groups: those who were anti-HBc positive (n = 31) and those who were anti-HBc negative (n = 85). Clinical data, including platelet counts at diagnosis and during follow-up, response to corticosteroid treatment and remission rates were analyzed.
resultsThe results indicated that anti-HBc positive patients had significantly lower platelet counts at diagnosis (p = 0.009) and a longer hospital stay (p = 0.042). Additionally, these patients demonstrated lower complete response rates to initial corticosteroid treatment at 1 month (p = 0.001) and 6 months (p = 0.021) compared to anti-HBc negative patients; however, there were no significant differences in overall response or durable response rates between the groups at 12 months. The risk of relapse was higher in anti-HBc positive patients (p = 0.041).
conclusionThese findings suggest that anti-HBc positivity may be associated with a more severe disease course and reduced treatment efficacy in ITP, highlighting the importance of assessing hepatitis B serological markers when managing ITP patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.